Merck & Co., Inc. and Lundbeck discontinue joint development program for gaboxadol, an investigational compound for insomnia

Merck & Co., Inc. and H. Lundbeck A/S announced today the discontinuation of
the joint development program for gaboxadol, an investigational new medicine
for the treatment of insomnia currently in phase III development. Data from
recently completed clinical studies suggest that the overall clinical profile
for gaboxadol in insomnia does not support further development.